1Alloford SL, Hunt BJ, Rose P, et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anemiss. Br J Med,2003,120(3) : 556 - 573.
2Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura, J Am Soc Nephrol, 2003,14(4) : 1072 - 1081
3Matsumoto M, Yagi H, Ishizashi H, et al. The Japanese experience with thromboeytopenie purpura- hemolytic uremic syndrome.Semin Hematol, 2004, 41 (1): 68- 74.
6Fontanas S, Kremer Hovinga JA, Studt JD, et al. Plasma therapy in thrombotic thrombocytopenic purpura: Review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS- 13 deficiency. Semin Hematol, 2004, 41 ( 1) :48 - 59.
7Coppo P, Bussel A, Chattier S, et al. High - dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocy-topenic purpura/hemolytic - uremic syndrome. Medicine (Baltimore), 2003, 82(1): 27-38.
8Zeigler ZR, Shadduck RK, Gryn JK, et al. Cryopreeipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apheresis, 2001,16( 1 ) :19 - 22.
9Cardigan R, Allford S, Williamson L. Levels of von Willebrand factor cleaving protease are normal in methylene blué treated fresh frozen plasma. Br J Haematol, 2002, 117 (2) : 253 - 254.
10Rizvi MA, Vesely SK, George JN, et al. Complicatiom of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura- hemolytic uremic syndrome.Transfusion, 2002, 40(8): 896-901.
2Tsai H M,Lian E C.Antibodies to Von Willebrand Factor-cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura[J].N Engl J Med,1998,339(22):1585-1594.
3Dong J F,Moake J L,Nolasco L,et al.ADAMTS-13 Radpdly Cleaves Newly Secreted Ultralarge Von Willebrand Factormultimesrs on the Endothelial Surface Under Flowing Conditions[J].Blood,2002,100(12):4033-4039.
4Raife T J,Lentz S R,A tkinson B S,et al.Factor V Leiden A Genetic Risk Factor for the Thrombotic Microangiopathy in Patients with Normal Von Willebrand Factor-cleaving Protease Activity[J].Blood,2002,99(2):437-442.
5Mandala M,Curigliano G,Bucciatelli P,et al.Factor V Leiden and G20210A Prothrombin Mutation and the Risk of Subclavian Vein Thrombosis in Patients with Breast Cancer and A Central Venous Catheter[J].Ann Oncol,2004,15(4):590.
6Coppo P,Bussel A,Charrier S,et al.High-dose Plasma Infusion Versus Plasma Exchange as Early Treatment of Thrombotic Thrombocytopenic Purpura/hemolytic-uremic Syndrome[J].Medicine (Baltimore),2003,82(1):27-38.
7Fakhouri F.Effiency of Curative and Prophylactic Treatment with Rituximab in ADAMTS-13 Deficient TTP:A Study of 11 Cases[J].Blood,2005,106(6):1932-1937.
8Mayer S A,Aledort L M.Throm Boti Microangiopathy:Differential Diagnosis,Pathoplysiology and the Rapeutic Strategies[J].Mt Sina J Med,2005,72(4):166-175.
